BVS — Bioventus Inc.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1665988 ·
Last close
$13.81
Market Cap
$943.29M
52W High
$15.89
52W Low
$6.26
ADV30
524,820
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 153,208,000 | 105,666,000 | 18,712,000 | 33,441,000 | 673,346,000 | 29,457,000 | 395,934,000 |
| Mar 2026 | 132,089,000 | 90,769,000 | 8,870,000 | 3,113,000 | 650,539,000 | 35,846,000 | 416,274,000 |
| Dec 2025 | 157,900,000 | 108,782,000 | 21,721,000 | 14,755,000 | 683,559,000 | 51,238,000 | 455,112,000 |
| Sep 2025 | 138,651,000 | 94,229,000 | 11,251,000 | 3,155,000 | 701,593,000 | 42,164,000 | 494,338,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$96,873,000
Investing CF
$-4,087,000
Financing CF
$-95,000,000
CapEx
$-2,587,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.77
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-298,375,000
Inventory
$79,807,000
Receivables
$138,406,000
ST Investments
—
EBIT TTM
$58,515,000
Pretax Income TTM
$38,638,000
Interest Exp TTM
$19,877,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$581,848,000
EBITDA
$80,145,000
Free Cash Flow
$67,764,128
Enterprise Value
$1,169,061,760
Total Cash
$30,394,000
Total Debt
$263,748,992
Shares Out
68,305,143
Trailing EPS
$0.78
Book Value
$3.35
ROE
25.7%
ROA
5.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 568,087,000 | 56,291,000 | 22,732,000 | 683,559,000 | 455,112,000 | 184,105,000 | 74,673,000 |
| Dec 2024 | 573,280,000 | 22,825,000 | -36,125,000 | 727,956,000 | 542,352,000 | 147,940,000 | 38,795,000 |
| Dec 2023 | 512,345,000 | 2,026,000 | -156,230,000 | 810,910,000 | 589,792,000 | 173,591,000 | 15,344,000 |
| Dec 2022 | 512,117,000 | -34,656,000 | -158,704,000 | 1,372,649,000 | 960,427,000 | 325,238,000 | -13,537,000 |
TTM Snapshot
Revenues TTM
$262,840,000
NetIncome TTM
$-7,802,000
OpCashFlow TTM
$0
Assets (Latest)
$683,559,000
Forward EPS
$0.92
Max Pain — expiry 2026-10-16
max pain strike: $10.00 · spot: $14.00 · call oi: 1,153 · put oi: 90
Expected Move to 2026-10-16:
±$6.25
(44.64%) —
implied range
$7.75 –
$20.25
· ATM straddle on $15.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BBNX | Beta Bionics, Inc. | $967.73M | $21.51 | — |
| CBLL | Ceribell, Inc. | $909.18M | $23.69 | — |
| PRCT | PROCEPT BioRobotics Corp | $979.00M | $17.20 | — |
| SGP | SpyGlass Pharma, Inc. | $905.44M | $27.07 | — |
| STVN | Stevanato Group S.p.A. | $1.05B | $21.13 | — |
News headlines (Yahoo Finance, 1h cache)
Bioventus (BVS) Q2 2026 Earnings Call Transcript
2026-08-13 13:17 · Yahoo
Bioventus (BVS) Stock Still Looks Like A Bargain On Earnings
2026-08-10 20:10 · Yahoo
The Bull Case For Bioventus (BVS) Could Change Following Its Q2 Earnings Surge And Reaffirmed 2026 Guidance
2026-08-10 07:10 · Yahoo
Is Bioventus (BVS) Stock Undervalued Right Now?
2026-08-07 13:40 · Yahoo
Is Bioventus (BVS) Stock Outpacing Its Medical Peers This Year?
2026-07-27 13:40 · Yahoo
Does Bioventus (BVS) Have the Potential to Rally 28.92% as Wall Street Analysts Expect?
2026-07-24 13:55 · Yahoo
Bioventus (BVS) Stock Looks Overvalued On Earnings Yet Backed By Broader Checks
2026-07-10 22:14 · Yahoo
Are You Looking for a Top Momentum Pick? Why Bioventus (BVS) is a Great Choice
2026-07-08 16:00 · Yahoo
Bioventus Inc. Q2 2026 Earnings Call Summary
2026-08-06 12:30 · Yahoo
Are Medical Stocks Lagging Bioventus (BVS) This Year?
2026-08-24 13:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.